GlassScriptPhysician profile
Corey Heichel
NPI 1134319601
$7,314.43
in general payments reported to CMS, 2019-2025
31 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,304 · 2022: $1,544 · 2023: $222 · 2024: $2,244 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,447 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,447.19 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,566.00 | 2021-2025 | |
| Amgen INC. | $1,112.04 | 2021-2025 | Otezla, Enbrel, Krystexxa |
| Ucb, INC. | $1,081.09 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $764.14 | 2021-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $434.72 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $217.32 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $209.40 | 2022-2025 | Acthar |
| Lilly USA, LLC | $203.70 | 2024-2025 | Taltz, Zepbound |
| Abbott Laboratories | $201.37 | 2021-2023 | Freestyle Libre 3 |
| Genzyme Corporation | $199.66 | 2025 | |
| Pfizer INC. | $186.26 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $159.86 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $149.88 | 2022-2025 | |
| Genentech USA, INC. | $134.51 | 2021-2024 | Actemra |
| Glaxosmithkline, LLC. | $129.08 | 2021-2025 | Benlysta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $98.50 | 2024 | Purified Cortrophin Gel |
| Sobi, INC | $82.97 | 2024-2025 | |
| Antares Pharma, INC. | $75.32 | 2021-2022 | |
| Radius Health, INC. | $44.24 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $32.16 | 2024 | Lupkynis |
| Kiniksa Pharmaceuticals International, Plc | $28.02 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $26.86 | 2022 | |
| Dexcom, INC. | $26.61 | 2021-2022 | |
| Amarin Pharma, INC. | $25.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.31 | 2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $20.11 | 2025 | Adalimumab-Aacf |
| Daiichi Sankyo INC. | $19.86 | 2022 | |
| Horizon Therapeutics Plc | $19.19 | 2022 | |
| Astellas Pharma US INC | $15.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.60 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Heichel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.